Our experienced team, who is in the field bringing AYVAKIT to patients with advanced systemic mastocytosis, is ready to expand our efforts upon FDA approval. In the coming year, we plan to scale the impact of AYVAKIT by addressing the medical needs of a substantially larger group of patients with an anticipated label expansion in indolent systemic mastocytosis, where AYVAKIT has the potential to be a disease modifying therapy and a major treatment advance. "Entering 2023, Blueprint Medicines is poised to achieve significant growth and value creation for patients and shareholders, leveraging our strong enterprise capabilities and infrastructure. Kate Haviland, Chief Executive Officer of Blueprint Medicines, said: 5, 2023 /PRNewswire/ - Blueprint Medicines Corporation (NASDAQ: BPMC) today outlined upcoming portfolio milestones advancing the company's 2027 Blueprint to achieve Precision at Scale, a five-year growth strategy to reach broad patient populations by leveraging its scientific leadership, proven development capability and integrated business infrastructure.
Morgan Healthcare Conference on Tuesday, January 10 at 4:30 p.m. Kate Haviland, Chief Executive Officer, to present company overview and 2023 outlook at 41 st Annual J.P. Anticipate multiple clinical data catalysts across mast cell disorder, EGFR-mutant non-small cell lung cancer, and breast cancer programs in 2023. Positioned for significant near-term growth with potential FDA approval of AYVAKIT® (avapritinib) in indolent systemic mastocytosis in the middle of 2023. Expect to achieve high-end of 2022 total revenue guidance of $180 million to $200 million and AYVAKIT product revenue guidance of $108 million to $111 million.
0 kommentar(er)
